Failed Merger Sparks Debate: Recent discussions on social media about STAAR Surgical have centered on the failed merger with Alcon, a deal that did not receive the necessary shareholder approval. Many users expressed frustration over the outcome, with the stock plummeting nearly 20% to around $20 per share following the announcement. The heavy selling pressure and heightened volatility have been hot topics.
Future Uncertainty: Sentiment on social media also reflects concerns about the company’s direction as it remains independent. Some argue that the downside risk at current levels may be limited, while others question management’s ability to drive growth, especially in key markets like China. The debate continues to fuel varied opinions on the stock’s next move.
Note: This discussion summary was generated from an AI condensation of post data.
STAAR Surgical Insider Trading Activity
STAAR Surgical insiders have traded $STAA stock on the open market 14 times in the past 6 months. Of those trades, 14 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $STAA stock by insiders over the last 6 months:
- PARTNERS, L.P. BROADWOOD has made 14 purchases buying 1,906,653 shares for an estimated $49,877,980 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
STAAR Surgical Revenue
STAAR Surgical had revenues of $94.7M in Q3 2025. This is an increase of 6.93% from the same period in the prior year.
You can track STAA financials on Quiver Quantitative's STAA stock page.
STAAR Surgical Hedge Fund Activity
We have seen 110 institutional investors add shares of STAAR Surgical stock to their portfolio, and 101 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ARMISTICE CAPITAL, LLC removed 2,812,000 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $75,558,440
- SOLEUS CAPITAL MANAGEMENT, L.P. removed 2,484,733 shares (-83.2%) from their portfolio in Q3 2025, for an estimated $66,764,775
- RESONA ASSET MANAGEMENT CO.,LTD. removed 2,421,836 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $65,074,733
- BALYASNY ASSET MANAGEMENT L.P. added 1,813,508 shares (+inf%) to their portfolio in Q3 2025, for an estimated $48,728,959
- MAGNETAR FINANCIAL LLC added 1,204,371 shares (+inf%) to their portfolio in Q3 2025, for an estimated $32,361,448
- BANK OF AMERICA CORP /DE/ removed 1,045,217 shares (-90.6%) from their portfolio in Q3 2025, for an estimated $28,084,980
- ALPINE ASSOCIATES MANAGEMENT INC. added 913,087 shares (+inf%) to their portfolio in Q3 2025, for an estimated $24,534,647
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
STAAR Surgical Price Targets
Multiple analysts have issued price targets for $STAA recently. We have seen 6 analysts offer price targets for $STAA in the last 6 months, with a median target of $28.0.
Here are some recent targets:
- John Young from Canaccord Genuity set a target price of $30.75 on 12/10/2025
- Simran Kaur from Wells Fargo set a target price of $30.75 on 12/10/2025
- Thomas Stephan from Stifel set a target price of $28.0 on 08/07/2025
- James Sidoti from Sidoti & Co. set a target price of $28.0 on 08/05/2025
- Anthony Petrone from Mizuho set a target price of $18.0 on 07/16/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
